US Bancorp DE Sells 91,299 Shares of Eli Lilly And Co (NYSE:LLY)

US Bancorp DE reduced its position in Eli Lilly And Co (NYSE:LLY) by 4.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,177,112 shares of the company’s stock after selling 91,299 shares during the period. US Bancorp DE’s holdings in Eli Lilly And Co were worth $241,202,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. FMR LLC increased its holdings in Eli Lilly And Co by 1.7% in the 1st quarter. FMR LLC now owns 13,916,001 shares of the company’s stock worth $1,805,741,000 after acquiring an additional 228,920 shares during the last quarter. Northern Trust Corp boosted its position in shares of Eli Lilly And Co by 0.3% during the 2nd quarter. Northern Trust Corp now owns 11,056,098 shares of the company’s stock valued at $1,224,906,000 after acquiring an additional 32,421 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of Eli Lilly And Co by 4.9% during the 2nd quarter. Fisher Asset Management LLC now owns 4,127,933 shares of the company’s stock valued at $457,334,000 after acquiring an additional 192,702 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Eli Lilly And Co by 8.1% during the 1st quarter. California Public Employees Retirement System now owns 3,162,898 shares of the company’s stock valued at $410,418,000 after acquiring an additional 238,198 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Eli Lilly And Co by 5.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 3,080,350 shares of the company’s stock valued at $399,706,000 after acquiring an additional 156,321 shares during the last quarter. Institutional investors own 76.78% of the company’s stock.

NYSE:LLY traded down $0.69 during mid-day trading on Friday, reaching $110.78. The stock had a trading volume of 1,492,859 shares, compared to its average volume of 3,204,832. The firm has a 50 day moving average price of $111.51 and a two-hundred day moving average price of $116.94. The stock has a market capitalization of $107.26 billion, a P/E ratio of 19.96, a P/E/G ratio of 1.96 and a beta of 0.16. Eli Lilly And Co has a one year low of $104.17 and a one year high of $132.13. The company has a debt-to-equity ratio of 4.98, a quick ratio of 0.87 and a current ratio of 1.13.



Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.45 by $0.05. The company had revenue of $5.64 billion during the quarter, compared to the consensus estimate of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. Eli Lilly And Co’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.48 EPS. Research analysts forecast that Eli Lilly And Co will post 5.73 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were paid a $0.645 dividend. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.33%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 46.49%.

A number of analysts have recently issued reports on LLY shares. Bank of America set a $120.00 price target on Eli Lilly And Co and gave the company a “neutral” rating in a research report on Tuesday. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Goldman Sachs Group began coverage on Eli Lilly And Co in a research report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price for the company. Finally, Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly And Co presently has an average rating of “Buy” and an average target price of $122.93.

In other Eli Lilly And Co news, SVP Stephen F. Fry sold 9,452 shares of Eli Lilly And Co stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $115.00, for a total value of $1,086,980.00. Following the transaction, the senior vice president now directly owns 100,211 shares of the company’s stock, valued at approximately $11,524,265. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Alfonso G. Zulueta sold 19,500 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total value of $2,201,745.00. Following the completion of the transaction, the senior vice president now directly owns 38,306 shares in the company, valued at $4,325,130.46. The disclosure for this sale can be found here. 0.11% of the stock is owned by insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: What is a trade deficit?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.